• Users Online: 175
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

STATE OF THE ART

Evolution, evidence and effect of secondary prophylaxis against rheumatic fever

Wyber Rosemary, Carapetis Jonathan

Year : 2015| Volume: 1| Issue : 1 | Page no: 9-14

   This article has been cited by
 
1 Challenging “business as usual” for acute rheumatic fever and rheumatic heart disease in Australia
Susan Welch,Aleena Williams,Adam Hort,Bhavini Patel
Journal of Pharmacy Practice and Research. 2020; 50(2): 119
[Pubmed]  [Google Scholar] [DOI]
2 The American Heart Association’s Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association
Andrea Beaton,Flavia B. Kamalembo,James Dale,Joseph H. Kado,Ganesan Karthikeyan,Dhruv S. Kazi,Chris T. Longenecker,Jeremiah Mwangi,Emmy Okello,Antonio Luiz P. Ribeiro,Kathryn A. Taubert,David A. Watkins,Rosemary Wyber,Meghan Zimmerman,Jonathan Carapetis
Circulation. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever
Rosemary Wyber,Ben J Boyd,Samantha Colquhoun,Bart J Currie,Mark Engel,Joseph Kado,Ganesan Karthikeyan,Mark Sullivan,Anita Saxena,Meru Sheel,Andrew Steer,Joseph Mucumbitsi,Liesl Zühlke,Jonathan Carapetis
Drug Delivery and Translational Research. 2016; 6(5): 572
[Pubmed]  [Google Scholar] [DOI]

 

Read this article